Answers are grounded in this paper and cite their sources.
Few data are available for surveillance decisions focusing on factors related to mortality, as the primary outcome, in intraductal papillary mucinous neoplasm (IPMN) patients.
No takes yet. Share an insight, caveat, or question.
Sekine et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: